Female libido drug remains in limbo - Local news, weather, sports Savannah | WSAV On Your Side

Raleigh pharma company appeals FDA's decision to block female libido drug

Posted: Updated:
A tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals. (AP Photo/Allen G. Breed) A tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals. (AP Photo/Allen G. Breed)
WASHINGTON -

The multi-decade search for a pill that boosts sexual desire in women has hit another roadblock, raising questions about the future of efforts to develop a female equivalent to Viagra.

Sprout Pharmaceuticals said Wednesday it has reached an impasse with the Food and Drug Administration over its drug, flibanserin. The daily pill is designed to increase libido in women by acting on brain chemicals linked to mood and appetite.

The FDA questions whether the drug's benefits outweigh its risks, considering its "modest" effectiveness and side effects including fatigue, dizziness and nausea.

Sprout, based in Raleigh, said it is appealing an October letter from the FDA that denied approval and asked for more information. But chances for approval appear slim: Of the 17 appeals FDA considered last year, 14 were denied, according to government figures.

The agency's latest rejection raises serious questions for more than a half-dozen companies working to develop therapies for women who report stress due to lack of libido. It's a market drugmakers have been trying to tap since the blockbuster success of Viagra, an erectile-dysfunction drug approved in the late 1990s to increase blood flow to the genitals.

But unlike sexual problems in men, most of women's sexual issues are psychological, not physical. As a result, there are a number of alternate causes doctors must consider before diagnosing female sexual desire disorders, including relationship problems, hormone disorders, depression and mood issues caused by other medications.

Experts say that developing drugs for female sexual dysfunction is so difficult because of how poorly we understand the root causes.

"Erectile dysfunction is a really easy thing to measure," says Emory University researcher Kim Wallen. "Motivation is a hard thing to measure and, quite honestly, we don't know enough about what creates sexual motivation to manipulate it."

And Dr. Virginia Sadock, a psychiatrist, says the idea that a single pill can restore female libido oversimplifies the problem. Even if the FDA eventually approves a drug for female sexual dysfunction, she says it will likely be used with non-drug techniques to reduce stress and improve self-image.

"A pill just doesn't take care of it," says Sadock, who teaches human sexuality at New York University's School of Medicine. "You may take a statin drug to control your cholesterol, great. But you should also exercise and you should also watch your diet."

Drugmakers have made several unsuccessful attempts at tweaking their approach to boosting female libido over the years. Initially, Pfizer tested Viagra on women, hoping that the drug's ability to increase blood flow to genitals would increase sex drive in women.

When that didn't work, drugmakers turned to hormones, including the male hormone testosterone. In 2004, an FDA panel rejected Procter & Gamble's testosterone patch, Intrinsa, due to questions about its long-term safety — despite evidence of effectiveness.

Sprout's flibanserin is the first drug to approach the problem through brain chemistry. Sprout acquired flibanserin from Boehringer Ingelheim in 2011, after the German drugmaker abandoned development of the pill following an FDA rejection letter.

Researchers believe the drug works by boosting dopamine — a brain transmitter associated with appetite — while lowering serotonin — another transmitter linked with feelings of satiation. Studies of the drug show that it boosts sexual desire, reduces stress and increases "sexually satisfying events," reported by women with hypoactive sexual desire disorder, or a lack of sexual appetite that causes stress.

Amanda Blackie of Nashville, Tenn., said she decided to enroll in a trial of the drug after noticing a lack of sexual interest in her fiancé. After a few weeks on flibanserin, Blackie said she got sexual cravings from simply talking to her partner on the phone — something she'd never experienced before.

Still, identifying the original source of her low libido is tricky. Like many women, Blackie talks about the demands of working a full-time job and caring for her teenage children.

"We're so consumed and so bogged down ... that most women are too tired to mess with it," Blackie, 50, says.

Despite experiences of women like Blackie, the FDA has twice rejected flibanserin since 2010. A key issue for the agency is that women taking the drug reported only 1.7 more satisfying sexual experiences per month than women taking placebo.

Sprout executives argue that number is statistically significant and warrants approval for their product, considering there are no other drugs approved for the condition.

"We've now got 24 drugs for men for either testosterone replacement or erectile dysfunction," says Cindy Whitehead, Sprout's chief operating officer. "Yet there are zero drugs for the most common form of sexual dysfunction in women."

The FDA, which does not comment on drugs under appeal, is expected to make a decision on Sprout's appeal in the first quarter of next year.

  • Most Popular StoriesMost Popular StoriesMore>>

  • Local Contractor Sued Over School Construction

    Local Contractor Sued Over School Construction

    Friday, July 25 2014 7:08 AM EDT2014-07-25 11:08:34 GMT
    Four minority subcontractors have sued Rives Worrell, a Savannah general contractor, who they say exploited their protected status to win the Hesse K-8 construction project.
    Four minority subcontractors have sued Rives Worrell, a Savannah general contractor, who they say exploited their protected status to win the Hesse K-8 construction project.
  • Sheriff's Office showcases "Faces of Meth" program as a lesson to all

    Sheriff's Office showcases "Faces of Meth" program as a lesson to all

    Monday, July 21 2014 11:33 AM EDT2014-07-21 15:33:26 GMT
    Faces of Meth™ is a project of the Multnomah County Sheriff's Office in Oregon. This project began when a deputy in the Corrections Division Classification Unit, Deputy Bret King, put together mug shots of persons booked into the Multnomah County Detention Center. Deputy King worked with his co-workers in the Classification Unit to identify people who had been in custody more than once. He then worked to verify criminal records and files to determine and assure a history of methamphetamine re...
    Faces of Meth™ is a project of the Multnomah County Sheriff's Office in Oregon. This project began when a deputy in the Corrections Division Classification Unit, Deputy Bret King, put together mug shots of persons booked into the Multnomah County Detention Center. Deputy King worked with his co-workers in the Classification Unit to identify people who had been in custody more than once. He then worked to verify criminal records and files to determine and assure a history of methamphetamine re...
  • Mysterious "woman in black" spotted in Tennessee

    Mysterious "woman in black" spotted in Tennessee

    A mysterious figure is capturing the attention of social media. She's been nicknamed "the woman in black" and she's been spotted in different parts of east Tennessee including Madisonville, Athens, Sweetwater and now Morgan County.
    A mysterious figure is capturing the attention of social media. She's been nicknamed "the woman in black" and she's been spotted in different parts of east Tennessee including Madisonville, Athens, Sweetwater and now Morgan County.
Powered by WorldNow

1430 East Victory Drive
Savannah, GA 31404

Telephone: 912.651.0300
Fax: 912.651.0320
Email: newsemailalert@wsav.com

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Media General Communications Holdings, LLC. A Media General Company.